KV Pharmaceutical changes its name – St. Louis Business Journal (blog)

Samantha Liss

Reporter- St. Louis Business Journal

Email  |  Twitter

After emerging from Chapter 11 bankruptcy last year, reorganizing, and naming new executives and board members, KV Pharmaceutical Co. is now ditching its name. The company will now be called Lumara Health Inc., according to a statement from the company.

The company will continue to focus on developing specialty pharmaceutical products for women.

In February, the company announced it had reorganized into two business units: maternal health and women’s health care. At that time, Gregg Raybuck was appointed as president of the maternal health division.

Then in May, Paul Williams was tapped to lead the women’s health care division as president.

Lumara, formerly KV, will continue to market its portfolio of specialty drugs, including its leading product, Makena, a drug used to help reduce the risk of preterm labor for pregnant women.

KV, led by CEO Greg Divis, emerged from Chapter 11 bankruptcy in September with “significantly reduced debt” and a $ 375 million recapitalization.

Health care, business of sports